[ad_1]
ValuEngine has upgraded Mediwound (NASDAQ: MDWD) in a report published on Tuesday, October 2.
Several other research companies have also recently published MDWD reports. Zacks Investment Research has brought Mediwound back from a portfolio note to a sales note in a report released on Wednesday, July 11. Oppenheimer set a price target of $ 14.00 on Mediwound and awarded the company a purchase note in a report released Monday, June 11. Finally, Wells Fargo & Co set a price target of $ 11.00 on Mediwound and awarded the company a purchase note in a report on Tuesday, September 25th. One badyst badigned a security rating and four badigned a purchase note to the security. Mediwound currently has a consensual rating from Buy and an average target price of $ 11.33.
NASDAQ shares: MDWD opened at $ 6.08 on Tuesday. Mediwound has a minimum of one year of $ 3.56 and a maximum of one year of $ 7.35. The company has a market capitalization of $ 163.64 million, a PE ratio of -9.81 and a beta of -0.13.
Mediwound (NASDAQ: MDWD) released its financial results on Tuesday, August 7th. The biopharmaceutical company reported EPS ($ 0.15) for the quarter, exceeding Zacks' consensus estimate ($ 0.20) of $ 0.05. Mediwound had a negative return on equity of 210.90% and a negative net margin of 783.30%. The company generated revenue of $ 1.03 million for the quarter, compared with a consensus estimate of $ 0.96 million. Research badysts predict that Mediwound will post a EPS of -0.71 for the current fiscal year.
Institutional investors and hedge funds have recently increased or decreased their holdings in equities. Nexthera Capital LP acquired a new position in Mediwound during the second quarter valued at $ 308,000. Wells Fargo & Company MN increased its stake in Mediwound by 19.9% in the first quarter. Wells Fargo & Company MN now holds 121,323 shares worth $ 631,000 from the biopharmaceutical company after purchasing 20,134 additional shares in the last quarter. Renaissance Technologies LLC increased its stake in Mediwound by 10.4% in the second quarter. Renaissance Technologies LLC now holds 130,500 shares of the $ 900,000 biopharmaceutical company after purchasing an additional 12,300 shares in the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. increased its participation in Mediwound by 1.0% in the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 2,098,277 shares valued at $ 14,478,000 in shares of the biopharmaceutical company after purchasing 21,559 additional shares in the last quarter. 32.58% of the stock is owned by hedge funds and other institutional investors.
About Mediwound
MediWound Ltd., an integrated biopharmaceutical company, focuses on the development, manufacture and commercialization of innovative therapeutic products that address unmet needs. It markets NexoBrid, a biopharmaceutical product intended for the elimination of pressure sore, dead or damaged tissue in adults suffering from deep thermal burns, of partial or total thickness, within the Union. European Union, Israel and Argentina.
See also: The role of a fiduciary investor and an individual investor
To view ValuEngine's full report, visit the official ValuEngine website.
Get news and ratings for Mediwound Daily – Enter your email address below to receive a concise daily summary of the latest news and reviews from Mediwound badysts and badociated companies with MarketBeat.com's FREE e-newsletter.
Source link
